Skip to main content
×
Login
Submit a Manuscript
Home
Journal
Current Issue
Archive
For Authors
Column Series
Research & Insight
Special Reports
Subscribe
Resources
Blogs
Expert Insights
Latest News
Pathways Beyond Oncology
Topics
Comparative Effectiveness Research
Cost-Effectiveness Research
COVID-19 Updates
Guideline Updates
Health Economics and Outcomes Research
Health Technology
Real-World Data
Reimbursement
Value-Based Care
Specialties
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
B-Cell Lymphoma
Biosimilars
Bladder Cancer
Breast Cancer
CAR-T Therapies
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Immuno-Oncology
Kidney Cancer
Liver Cancer
Lung Cancer
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Skin Cancer
Supportive Care
Excellence Forums
Mantle Cell Lymphoma Excellence Forum
Conferences
Oncology Clinical Pathways Congress
ASCO Gastrointestinal Cancers Symposium
ACCC Annual Meeting & Cancer Center Business Summit
ASCO Genitourinary Cancers Symposium
ASH Annual Meeting and Exposition
Oncology CME
About
About Us
Contact
Non-Small Cell Lung Cancer
Featured
Guideline Updates
NCCN Updates Clinical Practice Guideline for NSCLC
The NCCN released an update to include cemiplimab-rwlc as a preferred, category 1, treatment option for PD-L1 expression-positive NSCLC ≥50%.
News
Nivolumab Effective for Advanced NSCLC in Real-World Practice
Study results show nivolumab monotherapy is effective for previously treated advanced NSCLC in real-world practice.
News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
Higher out-of-pocket costs for TKIs are associated with decreased therapy adherence among patients with EGFR- and ALK-…
Quiz
Quiz: Impact of Out-of-Pocket Costs in NSCLC
True or False: Higher out-of-pocket costs for TKIs among patients with EGFR- and ALK-positive advanced NSCLC are…
News
Anticancer Therapy Small Driver of Unplanned Hospital Care for Patients With NSCLC
Study findings show TKI therapy, immunotherapy, and chemotherapy are relatively small drivers of unplanned acute…
News
Higher Out-of-Pocket Costs Associated With Decreased TKI Adherence in NSCLC
Anticancer Therapy Small Driver of Unplanned Hospital Care for Patients With NSCLC
Timely Specialty Palliative Care for NSCLC Associated With Cost-Savings
NGS Panel Using ctDNA Accurately Identifies Key Driver Alterations in Advanced NSCLC
Guideline Updates
NCCN Updates Clinical Practice Guideline for NSCLC
Interviews
Assessing a New Potential Standard of Care in First-Line Metastatic, Non-Squamous NSCLC
Videos
Exploring the New IVI NSCLC Value Modeling Platform
Podcast
Episode 28: Advances in NSCLC With Nathan Pennell
Conference Coverage
Nivolumab Plus Ipilimumab Associated With Lower Costs Than Other First-Line Regimens for NSCLC
Stay in the know.
Journal of Clinical Pathways Newsletter
Back to Top